Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis
Open Access
- 6 February 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-6
Abstract
The development of proteinuria restricts the dose of anti-angiogenic agents, thereby reducing their efficacy. Thus, this retrospective study was undertaken to identify predictive factors of the development of angiogenesis inhibitor-induced proteinuria, and to elucidate if there is a difference in the likelihood of proteinuria among anti-angiogenic agents or cancer types, to help guide future strategies to improve the safety, efficacy, and quality of life of patients receiving chemotherapy. Between April 2014 and February 2019, 124 cancer patients at our outpatient chemotherapy center who were receiving chemotherapy with bevacizumab, ramucirumab, or aflibercept were enrolled. Variables related to the development of proteinuria were extracted from the patients’ clinical records and used for regression analysis. The level of the proteinuria was evaluated based on CTCAE version 5. Multivariate ordered logistic regression analysis was performed to identify predictive factors for the development of proteinuria. The Wilcoxon/Kruskal-Wallis test was used to identify significant differences between groups. Significant factors identified included systolic blood pressure (SBP) [odds ratio (OR) = 1.031, 95% confidence interval (CI) = 1.005–1.058; P = 0.0197], number of cycles (OR = 1.049, 95% CI = 1.018–1.082; P = 0.0019), and calcium channel blocker use (OR = 2.589, 95% CI = 1.090–6.146; P = 0.0311). There was no difference among the three anti-angiogenic agents (P = 0.4969) or among cancer types (P = 0.2726) in the likelihood of proteinuria. In conclusion, SBP, number of cycles, and calcium channel blocker use were identified as significant predictors of the development of angiogenesis inhibitor-induced proteinuria. There was no difference among the three anti-angiogenic agents or among cancer types.Keywords
This publication has 21 references indexed in Scilit:
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialThe Lancet Oncology, 2014
- Improving the efficacy of RAAS blockade in patients with chronic kidney diseaseNature Reviews Nephrology, 2012
- Bevacizumab Increases Risk for Severe Proteinuria in Cancer PatientsJournal of the American Society of Nephrology, 2010
- Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of LosartanJournal of the American Society of Nephrology, 2008
- Understanding diagnostic tests 3: receiver operating characteristic curvesActa Paediatrica, 2007
- Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-AnalysisAmerican Journal of Kidney Diseases, 2007
- Nephrotic Syndrome After Bevacizumab: Case Report and Literature ReviewAmerican Journal of Kidney Diseases, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2005
- Traditional and Nontraditional Risk Factors Predict Coronary Heart Disease in Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2005